Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease and one of the world's most increasingly prevalent metabolic diseases. When NASH occurs, the buildup of fat in the liver causes liver inflammation and damage. Because of the damage, the liver doesn't work as well as it should. Scarring of the liver may result from NASH, eventually leading to cirrhosis. The condition is poised to become the leading cause of liver transplants in the near future. NASH is also frequently associated with other conditions, such as type 2 diabetes, obesity, and hypertension.
Verseon is developing a therapeutic treatment to combat fatty liver disease before it causes irreversible liver damage.
People currently have NASH worldwide
Addressable market in the developed world